Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $78.00 Average Target Price from Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have earned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $78.00.

Several research analysts have commented on LNTH shares. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Mizuho raised their price target on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Finally, Truist Financial lifted their price objective on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, December 18th.

Lantheus Stock Up 0.9%

Shares of LNTH opened at $73.87 on Wednesday. The firm has a fifty day moving average price of $67.24 and a 200-day moving average price of $59.58. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $4.90 billion, a P/E ratio of 31.04 and a beta of -0.08. Lantheus has a 12-month low of $47.25 and a 12-month high of $111.29.

Institutional Trading of Lantheus

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Elevation Point Wealth Partners LLC bought a new stake in Lantheus during the second quarter valued at about $26,000. Osterweis Capital Management Inc. purchased a new stake in shares of Lantheus during the second quarter valued at about $36,000. Hantz Financial Services Inc. boosted its holdings in shares of Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 396 shares in the last quarter. First Horizon Corp purchased a new position in shares of Lantheus in the 3rd quarter worth approximately $26,000. Finally, Smartleaf Asset Management LLC grew its position in shares of Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 197 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.